Image

Prof Özlem Türeci M.D., Co-Founder and CMO, BioNTech SE. Photo: BioNTech

The ACT RNA Club is inviting you for a very special session welcoming Professor Özlem Türeci, who will share her insights in immunotherapies which utilise the immune system's potential to fight cancer, infectious diseases and other serious diseases.

Agenda

This meeting will take place on Monday, 3rd February 2025, from 3pm to 4pm at the John Curtin School of Medical Research, ANU, with networking following from 4pm-4:30pm.

• 2:45 - 3:00pm: Guests to be seated
• 3:00 - 3:05pm: Welcome
• 3:05 - 4:00pm: Keynote address
• 4:00 - 4:30pm: Networking and nibbles

Speaker profile

Prof Özlem Türeci, M.D., Co-Founder and Chief Medical Officer of BioNTech, is a physician, immunologist, and cancer researcher with translational and clinical experience. 

Türeci has helped lead the discovery of cancer antigens, the development of mRNA-based individualized and off-the-shelf vaccine candidates and other types of immunotherapies which are currently in clinical development. Türeci leads the clinical development of BioNTech’s “Project Lightspeed,” the company’s successful effort to develop and distribute an mRNA-based vaccine against COVID-19, a historic achievement completed in less than one year. 

Türeci previously served as CEO and Chief Medical Officer of Ganymed Pharmaceuticals AG, which she co-founded with Ugur Sahin and Christoph Huber. She is also a professor for Personalized Immunotherapy at the University Medical Center Mainz and the Helmholtz Institute for Translational Oncology Mainz (HI-TRON) and currently serves as President of the Association for Cancer Immunotherapy (CIMT) in Germany. She is a recipient of the German Sustainability Award, among other notable recognitions.